Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.56 |
| ▸ | CALML3 | P27482 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080498 | 0.87 | CALML3 (0.50) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL3081527 | 0.85 | CALML3 (0.46) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL14763502 | 0.81 | MAOA (0.65) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL3093375 | 0.81 | MAOA (0.65) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL27820775 | 0.80 | CALML3 (0.43) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL19305235 | 0.79 | MAOB (0.41) | MAOACALML3MAOB | |
| SCHEMBL24923218 | 0.79 | MAOA (0.51) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL27944788 | 0.78 | CALML3 (0.43) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL27573559 | 0.77 | CYP2C19 (0.51) | MAOACALML3CYP3A4CYP2C19MAOB | |
| SCHEMBL27573562 | 0.77 | CYP2C19 (0.51) | MAOACALML3CYP3A4CYP2C19MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885CALML3 3842/4885CYP3A4 793/4885 |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885CALML3 3842/4885CYP3A4 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.